Company Analysis Propanc Biopharma, Inc.
1. Summary
Advantages
- The stock's return over the last year (179587.5%) is higher than the sector average (-4.97%).
- Current debt level 1310.4% has decreased over 5 years from 1666.67%.
- The company's current efficiency (ROE=52.8%) is higher than the sector average (ROE=13.16%)
Disadvantages
- Price (5.75 $) is higher than fair price (4.83 $)
- Dividends (0%) are below the sector average (1.73%).
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Propanc Biopharma, Inc. | Healthcare | Index | |
|---|---|---|---|
| 7 days | -35.3% | -6% | -1.8% |
| 90 days | -51.1% | -1.3% | -3.3% |
| 1 year | 179587.5% | -5% | 13.8% |
PPCB vs Sector: Propanc Biopharma, Inc. has outperformed the "Healthcare" sector by 179592.47% over the past year.
PPCB vs Market: Propanc Biopharma, Inc. has outperformed the market by 179573.65% over the past year.
Stable price: PPCB is not significantly more volatile than the rest of the market on "OTC" over the last 3 months, with typical variations of +/- 5% per week.
Long period: PPCB with weekly volatility of 3453.61% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (5.75 $) is higher than the fair price (4.83 $).
Price is higher than fair: The current price (5.75 $) is 16% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (31.91).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (51.38).
4.3. P/BV
P/BV vs Sector: The company's P/BV (-1456.17) is lower than that of the sector as a whole (3.26).
P/BV vs Market: The company's P/BV (-1456.17) is lower than that of the market as a whole (-9.02).
4.4. P/S
P/S vs Sector: The company's P/S indicator (0) is lower than that of the sector as a whole (3.22).
P/S vs Market: The company's P/S indicator (0) is lower than that of the market as a whole (4.71).
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-3583.13) is lower than that of the sector as a whole (10.21).
EV/Ebitda vs Market: The company's EV/Ebitda (-3583.13) is lower than that of the market as a whole (27.8).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -12.25% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-12.25%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-44.01%).
5.4. ROE
ROE vs Sector: The company's ROE (52.8%) is higher than that of the sector as a whole (13.16%).
ROE vs Market: The company's ROE (52.8%) is higher than that of the market as a whole (5.09%).
5.5. ROA
ROA vs Sector: The company's ROA (-2743.97%) is lower than that of the sector as a whole (6.08%).
ROA vs Market: The company's ROA (-2743.97%) is lower than that of the market as a whole (16.55%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (15.56%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (11.03%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.73%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
